Amneal reports Q1 2022 net revenue $498M (+1% YoY), GAAP net loss $2M, adj. EPS $0.12

Amneal Pharmaceuticals, Inc.

2022-Q1 EPS reported -$0.01 revenue$497,633,000

Net revenue $498M vs $493M in Q1 2021; driven by generics and AvKARE distribution, partially offset by Zomig loss of exclusivity.
GAAP net loss $2M ($0.01 diluted loss per share) vs net income $7M in Q1 2021.
Adjusted EBITDA $100M including $5M R&D milestone expense; adjusted diluted EPS $0.12.
Company maintains 2022 full-year outlook; highlights FDA approvals for two biosimilars and Saol Baclofen acquisition.
Growth strategy focused on biosimilars, injectables, and advancing R&D pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.